Company Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases.
It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).
The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development.
It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam’s base editing technology to discover new treatments for complement-driven diseases.
The company was incorporated in 2009 and is based in Waltham, Massachusetts.
| Country | United States |
| Founded | 2009 |
| IPO Date | Nov 9, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 702 |
| CEO | Dr. Cedric Francois M.D., Ph.D. |
Contact Details
Address: 100 Fifth Avenue Waltham, Massachusetts 02451 United States | |
| Phone | 617-977-5700 |
| Website | apellis.com |
Stock Details
| Ticker Symbol | APLS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001492422 |
| CUSIP Number | 03753U106 |
| ISIN Number | US03753U1060 |
| Employer ID | 27-1537290 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Cedric Francois M.D., Ph.D. | Co-Founder, President, Chief Executive Officer and Director |
| Dr. Pascal Deschatelets Ph.D. | Co-Founder and Chief Scientific Officer |
| Alec Machiels J.D., MBA | Co-Founder and Director |
| Timothy E. Sullivan | Chief Financial Officer and Treasurer |
| Adam J. Townsend | Chief Operating Officer |
| David O. Watson Esq., J.D. | General Counsel |
| James G. Chopas CPA | Vice President, Corporate Controller and Chief Accounting Officer |
| Meredith Kaya | Senior Vice President, Investor Relations and Strategic Finance |
| Karen Lewis | Chief People Officer |
| Prof. Peter Hillmen M.D., Ph.D. | Head of Hematology Engagement and Member of PNH Scientific Advisory Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 21, 2024 | 144 | Filing |
| Jun 5, 2024 | 8-K | Current Report |
| May 14, 2024 | 8-K | Current Report |
| May 8, 2024 | 144 | Filing |
| May 7, 2024 | 10-Q | Quarterly Report |
| Apr 26, 2024 | ARS | Filing |
| Apr 26, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 26, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 8, 2024 | 144 | Filing |
| Apr 1, 2024 | 144 | Filing |